CA-BIOCELL-TECHNOLOGY
13.6.2019 02:53:04 CEST | Business Wire | Press release
BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).
The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).
For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:
- Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
- Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
- Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
- Decreased skin dryness and erythema.
- No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.
“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.
The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.
“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.
“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.
About BioCell Collagen ®
BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .
About BioCell Technology, LLC
BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005972/en/
Contact:
Suhail Ishaq President of BioCell Technology, LLC 714-632-1231
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
